View Press Releases
-
Meet CD Genomics at the SITC 37th Annual Meeting
Oct 31, 2022
-
Extensive Options for Graphene Quantum Dot Modifications
Oct 31, 2022
-
Pretreatment Chemicals Make Electroplating More Efficient
Oct 31, 2022
-
BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022.
Oct 31, 2022
-
Proscia Presents Study Results On New Artificial Intelligence That Predicts Diagnostic Concordance For Melanoma
Findings illustrate promise of technology to lower misdiagnosis rate for deadliest form of skin cancer
Oct 31, 2022
-
Creative Biogene Develops Custom Lentivirus Services to Support Stable Cell Line Generation
Oct 31, 2022
-
Microbiosci Releases LPS Extraction Service to Support Managing Endotoxins Issues
Oct 31, 2022
-
Nanoparticle Development Services for Drug Delivery System Research
Oct 31, 2022
-
Creative Biogene Delivers Knockout Mouse Models to Support Gene Editing and Future Studies
Oct 31, 2022
-
Acylation Reagents for Gas Chromatography and Other Instrumental Analytical Methods
Oct 31, 2022
-
ExoQuali Products and Protocols Released by Creative Bioarray to Easy Exosome Isolation Process
Oct 31, 2022
-
Histobiolab Provides Over 150 Fish Probes to Satisfy Precise Biological Research Needs
Oct 31, 2022
-
Creative Bioarray Provides 3D Cell Patterning Service Based to Speed up Drug Screening
Oct 31, 2022
-
PubHive Upgrades SaaS Platform to MedDRA Version 25.1
Drug safety and pharmacovigilance (DSPV) teams that license access to the PubHive Navigator platform can now access the newest MedDRA version when performing signal evaluation and reporting activities
Oct 31, 2022
-
Terumo Pharmaceutical Solutions expands CDMO services outside Japan for global market
Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has today announced it will expand its contract development and manufacturing services for parenteral drugs to global customers.
Oct 30, 2022
-
MULTI-LEVEL & MULTI-ANALYTE LIQUID STABLE CLINICAL ENZYME CALIBRATION VERIFIERS AVAILABLE FROM VERICHEM
Oct 30, 2022
-
CARLSBAD, Calif. (Oct. 31, 2022) – Thermo Fisher Scientific introduces new dPCR wastewater surveillance kit and RNA master mix to simplify detection of SARS-CoV-2 targets
Oct 30, 2022
-
New NoriZite™ Nasal Spray launches in the UK
Birmingham Biotech LTD, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, today announces that NoriZite™ Nasal Spray, an easy-to-use nasal device designed to block and trap inhaled virus particles, is now available to buy in the UK.
Oct 27, 2022
-
Samsung Biologics Reports Third Quarter 2022 Financial Results
Samsung Biologics reports third quarter 2022 financial results
Oct 27, 2022
-
Abundent Application Potentials of Nanomaterials
Oct 27, 2022


